Clinical trials: Systemic Sclerosis
Systemic Sclerosis, Scleroderma
Cardiac Safe Transplants for Systemic Sclerosis
This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
- Trial name
- CAST (NCT03593902)
- Testing
- Rituximab, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Diffuse Cutaneous Systemic Sclerosis, Scleroderma
Brentuximab Vedotin for Systemic Sclerosis
There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin, a drug-antibody conjugate approved…
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
- Trial name
- BRAVOS (NCT03222492)
- Testing
- Brentuximab Vedotin
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Scleroderma
Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
The purpose of this study is to learn about the effect atorvastatin on blood vessel function and Raynaud symptoms in patients with early diffuse systemic sclerosis.
- Trial name
- TAMER (NCT02370784)
- Testing
- atorvastatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Systemic Sclerosis, Shortness of Breath
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis.
- Conditions
- Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
- Trial name
- NCT01051960
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles